Kaufman & Broad S.A. (FRA:3GH)

Intra-Cellular Therapies Revenue

Kaufman & Broad had revenue of 249.34M EUR in the quarter ending May 31, 2025, with 11.07% growth. This brings the company's revenue in the last twelve months to 1.12B, up 10.96% year-over-year. In the fiscal year ending November 30, 2024, Kaufman & Broad had annual revenue of 1.08B, down -23.58%.

• Revenue (ttm): 1.12B
• Revenue Growth: +10.96%
• P/S Ratio: 0.54
• Revenue / Employee: 1.70M
• Employees: 641
• Market Cap: 606.99M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Nov 30, 2024	1.08B	-332.29M	-23.58%
Nov 30, 2023	1.41B	94.18M	7.16%
Nov 30, 2022	1.31B	33.08M	2.58%
Nov 30, 2021	1.28B	118.75M	10.21%
Nov 30, 2020	1.16B	-309.10M	-21.00%